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iNKT cells are a subset of innate-like T cells that utilize an invariant TCR alpha chain 
complexed with a limited repertoire of TCR beta chains to recognize specific lipid anti-
gens presented by CD1d molecules. Because iNKT cells have an invariant TCR, they 
can be easily identified and targeted in both humans and mice via standard reagents, 
making this a population of T cells that has been well characterized. iNKT cells are some 
of the first cells to respond during an infection. By making different types of cytokines 
in response to different infection stimuli, iNKT cells help determine what kind of immune 
response then develops. It has been shown that iNKT cells are some of the first cells 
to respond during infection with a pathogen and the type of cytokines that iNKT cells 
make help determine the type of immune response that develops in various situations. 
Indeed, along with immunity to pathogens, pre-clinical mouse studies have clearly 
demonstrated that iNKT cells play a critical role in tumor immunosurveillance. They can 
mediate anti-tumor immunity by direct recognition of tumor cells that express CD1d, 
and/or via targeting CD1d found on cells within the tumor microenvironment. Multiple 
groups are now working on manipulating iNKT cells for clinical benefit within the context 
of cancer and have demonstrated that targeting iNKT cells can have a therapeutic bene-
fit in patients. In this review, we briefly introduce iNKT cells, then discuss preclinical data 
on roles of iNKT cells and clinical trials that have targeted iNKT cells in cancer patients. 
We finally discuss how future trials could be modified to further increase the efficacy of 
iNKT cell therapies, in particular CAR-iNKT and rTCR-iNKT cells.
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iNTRODUCTiON
T cells utilize their unique T cell receptor (TCR) αβ or γδ chain pairs to recognize the universe 
of antigens. Although many TCRs with extensive somatic V-D-J gene rearrangements recognize 
peptide antigens within the context of MHC molecules, this is not the only type of antigen that can 
be recognized. T cells can also utilize near-germline V-J TCR rearrangements to recognize vitamin 
metabolites, small phosphoantigens, and lipid antigens presented within various highly conserved 
and non-polymorphic MHC-I like molecules (1–3). Collectively, these non-peptide-recognizing 
T  cells are called “innate-like” T  cells and make up a significant proportion of the mammalian 
T  cell compartment (1–4). Importantly, new research is suggesting that these innate-like T  cells 
have important roles in regulating immune reactions not only to pathogens but also to tumors, 
making them potentially exploitable T cell populations for immunotherapy (1–6). One of the best 
FigURe 1 | Invariant NKT (iNKT) cell contribution to initiating immune reactions via a positive feedback loop with dendritic cells (DCs). The contribution of iNKT cells 
to immune surveillance is linked to DC maturation. DCs produce IL-12 and present lipid antigens on CD1d (an MHC class 1 homolog) to stimulate iNKT cell 
production of IFNγ. The relative contribution of IL-12 or lipid-CD1d to iNKT cell activation is variable and context dependent. Activated iNKT cells produce IFNγ and 
co-stimulate DCs via CD40L-CD40 interactions to promote DCs to produce IL-12. This IL-12 then further activates iNKT cells in a positive feedback loop. Following 
activation of iNKT cells, iNKT cell-produced IFNγ and other iNKT-DC interactions (e.g., CD40L-CD40) mature DCs and promote production of IL-12, which further 
activates iNKT cells in a positive feedback loop.
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characterized innate-like T  cell subsets that is being leveraged 
in immuno-oncology are Natural Killer T (NKT) cells, which 
recognize lipid antigens bound within the antigen presentation 
molecule CD1d. The best-characterized subset of NKT  cells is 
“invariant” or “iNKT” cells (1–6). Mouse and human iNKT cells 
are sufficiently conserved that they can respond to each other’s 
CD1d (7).
OveRview OF iNKT CeLL BiOLOgY
NKT cells are a heterogenous population of innate-like CD1d-
restricted T  cells, the best known of which are invariant NKT 
(iNKT) cells (1–9). iNKT  cells utilize a near-germline TCRα 
rearrangement (Vα24-Jα18 in humans and Vα14-Jα18 in mice) 
combined with a limited TCRβ repertoire (1–4). iNKT cells were 
originally named because of expression of NK1.1 (CD161C) 
in some mouse strains (CD161A in humans) but this does not 
accurately define iNKT cells (5, 6). Instead, iNKT cells are func-
tionally defined by their ability to respond to the lipid antigen 
α-galactosylceramide (α-GalCer) when bound within CD1d 
molecules and/or by utilizing monoclonal antibodies against the 
human invariant TCRα chain (3–8). By utilizing (imperfect) co-
expression of NK and T cell markers, absence in CD1d or Jα18 
KO mice, CD1d tetramers loaded with α-GalCer, or other meth-
ods, iNKTs were discovered to make up a significant proportion 
of T cells within the mouse liver (~20−50%) and adipose tissue 
(~10−25%) and are present in significant numbers (~0.5−2%) 
within the murine thymus, spleen, blood, and bone marrow (3–6). 
Within humans, iNKT cells are represented at similar frequencies 
to mice in adipose tissue, but are much less frequent in the liver 
and other organs where “non-invariant” or “diverse” NKT cells 
predominate (6, 8, 9). In human peripheral blood, iNKT  cells 
range between undetectable to over 1% of circulating T  cells 
in rare individuals, with a median percentage of approximately 
0.05% (6, 8, 9).
Unlike peptide-MHC restricted T  cells, which emerge from 
the thymus “naïve,” iNKT cells leave the thymus fully matured 
and able to perform their effector functions without priming 
(3–6). Within the periphery, iNKT cells respond to lipid antigen 
and/or cytokine (e.g., IL-12/18) exposure by rapid secretion of 
multiple cytokines (3–6). Depending on how the iNKT cells are 
activated, this can include both regulatory cytokines (e.g., IL-4, 
IL-10, by analogy with Th2, Treg, etc., especially from NKT2, 
NKT10) (3–6) and/or pro-inflammatory cytokines (e.g., IL-2, 
IL-17, TNFα, and/or IFNγ, particularly NKT1 or NKT17) (3–6). 
Since iNKT cells respond rapidly and without the need for prim-
ing, they are some of the first cells within an immune response 
to be activated and therefore act as a “bridge” between the innate 
and adaptive immune systems. Indeed, iNKT cell activation via 
TCR engagement or IL-12 or both causes iNKT cells to upregu-
late IL-12 receptor [which is already basally expressed at a higher 
level than in NK  cells (6, 8)] and CD40L, while also inducing 
maturation and production of IL-12 in dendritic cells (DCs). This 
IL-12 release then in turn greatly increases IFNγ production by 
iNKT cells, leading to a positive feedback loop for Th1 immunity 
(Figure 1) (3–6, 8, 9). Additionally, this maturation of DCs leads 
to trans-activation of NK cells and increased MHC class I and 
II antigen presentation to T cells as well as direct cognate B cell 
“help,” allowing for both innate and adaptive immune responses 
to be established (3–6).
Invariant NKT cells can be further subdivided into additional 
subsets based on anatomical location or by surface activation 
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markers and transcription factors (1–6). The key master tran-
scription factor of at least iNKT cell development and present in 
most mature iNKT populations is PLZF (4). Unlike most MHC-
restricted T cells that are either CD4 + or CD8α + , iNKT cells 
in mice are either CD4 + or CD4/CD8αβ double negative (DN) 
(3–6). In humans, a minor population of iNKT  cells (typically 
1–5%) can instead express CD8αβ (3, 10). Additionally, CD8αα 
homodimers are expressed by other activated human T  cells, 
although at lower levels on activated CD4 + T cell subsets lack-
ing CD8β (1, 2, 11). In general, CD4 +  iNKT  cells are able to 
express more Th2-related cytokines like IL-4, although they can 
express as much Th1 cytokines at the same time (3–9). Human 
CD8αβ +  and DN iNKT  cells are biased toward a Th1-related 
phenotype, more cytotoxic and preferentially make IFNγ. In both 
cases, these are plastic definitions and CD4 +  iNKT  cells can 
make IFNγ and DN iNKT cells can make IL-4, at least partially 
depending on the stimuli given (3–6, 8, 9). Mouse iNKT cells are 
less clearly biased, although liver iNKT cells have greater anti-
tumor activity than other organ iNKT cells (12). Indeed, within 
different organs, different iNKT phenotypes tend to dominate. 
Relatively Th1-like iNKT  cells tend to be enriched within the 
spleen and liver, while Th2-like iNKT  cells are associated with 
the lungs and intestine (3–6). There are also Th17-like iNKT cells 
that express cytokines like IL-17 and are enriched within the 
lungs, intestine, lymph nodes, and skin (13). Finally, a subset has 
recently been described in adipose tissue. Adipose iNKT tend to 
make anti-inflammatory cytokines like IL-10 and unlike other 
mature iNKT cells, lack PLZF (14, 15).
Because iNKT cells can rapidly produce IFNγ, IL-4, or both, 
they have been found to play a role in various diseases by establish-
ing a Th1- or Th2-based immune response. In bacterial and viral 
infections, iNKT cells typically help in early control of the patho-
gen by establishing a productive Th1 response (1–6, 9, 13, 16). In 
both mouse and human studies, roles for iNKT cells have been 
described in diseases associated with excessive Th1 responses like 
type 1 diabetes (9) and chronic obstructive pulmonary disease 
(17, 18). Roles have also been described for iNKT cells helping to 
suppress Th1 responses and drive tolerogenic responses to grafts. 
As an example, following hematopoietic stem cell transfer, the 
presence of iNKT cells is predictive for survival with a reduction 
in graft versus host disease (GvHD) in patients and preclinical 
models (8, 9, 19–21).
iNKT CeLLS iN CANCeR
Within the context of cancer, the frequency and/or function of 
iNKT  cells (either within the tumor or in circulation) can be 
selectively and highly correlative with overall survival. In human 
studies, this has been demonstrated in prostate cancer, medul-
loblastoma and neuroblastoma, melanoma, colon, lung, breast, 
and head and neck squamous cell carcinomas (8, 9, 22–37). The 
largest numbers of patient samples and/or longest follow-ups 
were analyzed for tumor in neuroblastoma and circulating in 
head and neck squamous cell carcinomas, respectively (26, 37). 
Consistent with reduced numbers, proliferative response defects 
of iNKT cells have been noted in cancer patient iNKT cells (23, 
28, 37). Decreased numbers of circulating iNKT  cells can be 
accompanied by decreases in IFNγ production and a concurrent 
increase in IL-4 production (22, 24, 25, 35). Importantly, all of 
these defects including the shift toward an iNKT cell Th2 pheno-
type can be reversed in vitro. Activation via 2 strong stimuli, such 
as α-GalCer and IL-12, increases iNKT  cell IFNγ production, 
promotes tumor rejection, and protects from development of 
metastasis in multiple mouse models and enhances cancer patient 
iNKT Th1 responses in vitro (8, 22, 24, 25, 35). However, such 
stimuli do not reverse iNKT defects individually (particularly in 
advanced disease) (8, 22, 24, 25, 35). Additionally, injection of 
α-GalCer-pulsed DCs (particularly mature DC) can provide a 
strong anti-tumor effect (31, 34, 35).
ROLe OF iNKT CeLLS iN CANCeR:  
PRe-CLiNiCAL MOUSe MODeLS
While the human data is correlative, the role for iNKT cells in 
providing tumor surveillance has been well-characterized in 
mouse models. Examples of iNKT-mediated tumor clearance 
were demonstrated by the lab of Taniguchi et al. (31, 38) as well 
as those of Smyth and Godfrey (9, 12). iNKT cells were found to 
be essential for anti-tumor responses induced by α-GalCer (12, 
30, 38). Treatment with carcinogen or transfer of carcinogen-
induced tumor cell lines in mice lacking iNKT  cells (via TCR 
Jα18 deletion, Jα18-KO) caused tumors to appear at a much 
higher frequency than in wild-type (WT) mice (39). Additionally, 
transfer of iNKT cells into Jα18-KO mice was sufficient to cause 
protection against tumors to a level like WT mice, unless the 
iNKT cells came from an IFNγ KO mouse (39). Together, these 
and other results show that even in the absence of exogenous 
antigens like α-GalCer, iNKT cells can establish a Th1 response to 
some tumors and can contribute to tumor clearance (8, 9, 29, 32, 
39). Further support for iNKT cell-mediated tumor surveillance 
was obtained with the spontaneous prostate cancer mouse strain: 
transgenic adenocarcinoma of the mouse prostate (TRAMP). By 
back-crossing Jα18-KO to TRAMP mice, Bellone et al. suggested 
that lack of iNKT cells led to accelerated tumor generation and 
quicker mortality than was detected in WT TRAMP mice (39), 
consistent with earlier human in vitro data (22). However, more 
recently, a caveat of studies using the original Jα18 KO mice 
(38) has come to light, most notably the inability of these mice 
to express TCR Jα regions past Jα19 (40). This impacts the TCR 
repertoire of conventional T cells, which could also impact in vivo 
immune responses, so new Jα18 KO mice have been developed 
that do not share this defect (41, 42).
While some CD1d-expressing tumors can probably cause 
Th1-biased iNKT cell activation, progressive chronic tumor cell 
growth can also apparently directly cause Th2-biased iNKT cell 
activation. By utilizing the same TRAMP prostate cancer model 
as a source of primary prostate tumors, we demonstrated that 
CD1d-expressing prostate tumor cells can directly activate 
iNKT cells, but biased them toward making Th2 cytokines (43). 
While addition of α-GalCer or IL-12 can usually help bias an 
iNKT cell toward a Th1 phenotype, neither of these stimuli on 
their own were enough to reverse the tumor cell driven Th2 bias 
in iNKT cells. However, pulsing the tumor cells with α-GalCer 
FigURe 2 | Invariant NKT (iNKT) cell activity within the tumor microenvironment (TME). iNKT cells can function within the TME via direct or indirect interactions with 
tumor cells. (A) In the direct activation pathway, iNKT cells recognize lipid-CD1d complexes on the surface of tumor cells and then directly mediate killing of tumor 
cells. By making inflammatory cytokines like IFNγ, this also helps TME-resident NK cells perform their anti-tumor cell effector functions (24, 35, 36, 43, 44). (B) In the 
indirect activation pathway, iNKT cells recognize lipid-CD1d complexes on the surface of TME-resident antigen presenting cells (APCs) or tissue-associated 
macrophages (TAMs) (29). This interaction leads to iNKT cell-mediated killing of immunosuppressive TAMs, leading to a less immunosuppressive environment where 
tumor-infiltrating NK cells can better perform their functions. Alternately, if the CD1d is on the surface of a TME-resident APC, the iNKT cell can activate that APC 
and stimulate production of IL-12, helping resident effector cells like NK cells overcome the immunosuppressive state of the tumor (32).
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and adding IL-12 at the same time synergized to allow for IFNγ 
production to occur (43).
In both the models described above and in humans, activation 
of iNKT cells and tumor rejection can occur in one of two ways 
(Figure 2). The first is that iNKT cells directly recognize and kill 
CD1d-expressing tumor cells. This can occur in a significant 
portion of lymphomas, early myeloma, myeloid leukemias, 
medulloblastoma, and prostate cancers (24, 35, 36, 43, 44). The 
second is by activation of iNKT cells by other CD1d-expressing 
cells in the tumor microenvironment (TME) (29, 32). In this 
indirect system, iNKT cell activation by CD1d-expressing TME 
cells leads to trans-activation of NK cells and/or killing of immu-
nosuppressive cells like tumor-associated Macrophages (TAMs) 
(29, 32, 45). When we directly tested the ability of iNKT cells to 
respond to CD1d-expressing prostate tumor cells from TRAMP 
mice in vitro, we found that they did not elicit a Th1 phenotype 
that would be indicative of killing (43). However, Bellone et al. 
found that iNKT cells do help delay tumor growth within intact 
TRAMP mice over periods of months (39). The differences in 
these two studies may include that within the intact mouse there 
is also a role for iNKT  cells in killing CD1d-expressing TAMs 
independent of any direct anti-tumor interactions (29, 32). 
Therefore, relieving some of the immunosuppression within the 
primary tumor by killing TAMs may be a key role for iNKT cells 
in vivo. However, in progressive clinical cancer, TAMs can appar-
ently overwhelm iNKT cells (29, 32). Reversing these as well as 
tumor cell-driven iNKT defects is the goal of the groups working 
on clinical trials targeting iNKT cells worldwide.
PReCLiNiCAL AND CLiNiCAL TRiALS 
TARgeTiNg iNKT CeLLS
Pre-clinical murine models have shown similar defects in 
iNKT  cells as have been seen in humans and demonstrated 
that iNKT stimulation in  vivo or adoptive transfer can induce 
strong antitumor immune responses (38, 43, 46–51). This has 
been shown to be the case for stimulation of iNKT  cells via 
α-GalCer infusion and when α-GalCer has been loaded on DCs 
(46–51). Additionally, as iNKT cells play a key role in generating 
a positive feedback loop for IL-12 production by DCs, low and 
moderate-dose IL-12 therapy in animal models is also dependent 
on iNKT cells (46, 50, 51). Either stimulation causes iNKT cells 
to rapidly produce a strong cytokine response, including large 
amounts of IFN-γ that stimulates NK cells, B cells, and that also 
enhances the generation of classical cytotoxic T  cell responses 
(39, 49, 51). Strong antitumor immune responses to α-GalCer 
and/or IL-12 have been observed in most murine models, includ-
ing colon carcinoma, lymphomas, sarcoma, melanoma, prostate, 
and lung carcinoma (39, 41, 46–51). Together, these observations 
indicate that restoration of iNKT cell function in humans with 
cancer may stimulate potent antitumor immune responses.
Clinical Trials Targeting iNKT Cells via 
Stimulation with α-galCer
The pre-clinical antitumor effects of α-GalCer stimulated a 
phase 1 clinical study in advanced-stage cancer patients (52). 
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Administration of α-GalCer was not accompanied by dose 
limiting toxicity. In this phase 1 study, as in other analyses 
(9, 28, 29, 37), circulating iNKT  cell numbers were found 
to be decreased in cancer patients (52). The relevance of the 
decreased size of the iNKT cell pool was demonstrated in the 
same trial as immunological responses to α-GalCer adminis-
tration (increases in GM-CSF and TNF-α) were only observed 
in those patients with higher iNKT  cell levels comparable to 
healthy controls (52).
This initial clinical study and preclinical studies outlined above 
implied that antitumor effects of α-GalCer in cancer patients 
would be limited by both qualitative and quantitative defects in 
iNKT cells, necessitating the evaluation of alternative approaches 
to exploit this natural antitumor system. In mice, administration 
of α-GalCer-loaded DC resulted in a more powerful antitumor 
immune response (48, 49). Several phase 1 clinical studies have 
used α-GalCer-loaded immature or matured monocyte-derived 
dendritic cells (Mo-DC) or other monocyte-derived antigen-
presenting cell (APC) preparations leading to clinically relevant 
antitumor responses (53–58).
In the first published autologous Mo-DC transfer clinical 
study, Nieda et al. investigated the transfer of purified α-GalCer-
pulsed immature Mo-DC in a variety of different malignancies 
(53). They found that adoptive transfer of α-GalCer-pulsed 
Mo-DC led to minor systemic side effects in 9 of 12 patients such 
as fever, malaise, lethargy, and headache (53). These side effects 
were temporary and expected when eliciting an immune response 
by activating iNKT  cells. Several patients experienced tempo-
rary exacerbation of tumor symptoms that were interpreted as 
inflammatory responses to the tumor (e.g., enlargement of tumor 
deposits or associated lymph nodes, bone pain, and respiratory 
symptoms in subjects with pulmonary metastases) (53). These 
exacerbated tumor symptoms had a strong temporal and repro-
ducible relationship in terms of timing and nature with treatment 
cycles, were transient (generally lasting 1 to 3  days), and were 
absent outside of the study period. In four of the patients, there 
were decreases in tumor markers, and in one patient, there was 
extensive tumor necrosis (53). This study was also important in 
that it was the first to provide clinical interventional data for the 
role of iNKT cells as the “bridge” between the innate and adaptive 
immune systems in humans, as has been seen in multiple human 
in vitro and murine in vivo studies (39, 43, 46–51). In this clinical 
trial, activation of human iNKT cells in vivo by adoptive transfer 
of α-GalCer-loaded Mo-DC reproducibly initiated an activation 
program wherein iNKT cell activation led to subsequent activa-
tion of B cells, T cells, NK cells, and increased serum levels of 
IL-12 and IFN-γ (53).
Ishikawa et al. investigated the effects of adoptive transfer of 
autologous cell preparations that were enriched for α-GalCer-
pulsed DCs in 11 patients with recurrent lung cancer or advanced 
non-small cell lung cancer (54). No serious adverse events were 
reported. Importantly, in several patients, an increase in the 
circulating number of iNKT cells was also detected. Notably, as 
reported previously, immunological responses were restricted to 
patients having “normal” pretreatment iNKT cell numbers. No 
patients exhibited complete or partial responses in this study, but 
two patients had stable disease (54).
Chang et  al. performed a clinical trial where five cancer 
patients were treated with α-GalCer-pulsed mature Mo-DC (55). 
The trial was focused on evaluating the number and phenotype 
of iNKT  cells following stimulation via DC transfer. A more 
than 100-fold expansion of circulating iNKT cell numbers was 
observed in all five patients, and this expansion was sustained for 
up to 6 months post-vaccination (55). Additionally, the data sug-
gested a boost in adaptive T cell immunity, as it was accompanied 
by an increase in antigen-specific memory CD8 + T cells (55). 
In this study, no more than grade 1 toxicity was observed, and 
although one patient developed rheumatoid factor and transient 
positive anti-nuclear antibody at follow up, no clinical evidence 
of autoimmunity was observed (55).
In addition to these trials above, several subsequent trials have 
used APC (i.e., adherent monocytic cells treated with GM-CSF 
and IL-2) loaded with α-GalCer and have shown increasing effec-
tiveness as dose and targeting have been improved, particularly so 
far in lung cancer and head and neck cancers (56–58). Specifically 
in a lung cancer trial, patients who had circulating iNKT able to 
produce IFNγ had a threefold longer lifespan (57).
Clinical Trials Boosting endogenous iNKT 
Cell Numbers via Adoptive Transfer
Another (and complementary) approach to α-GalCer-based 
treatments involves the adoptive transfer of activated iNKT cells 
to restore iNKT cell numbers and potentially iNKT cell function 
in cancer patients. This approach has been tested in preclinical 
models of melanoma and lung cancer and shown to be more 
effective compared to the i.v. administration of α-GalCer (50). 
Trials of iNKT-enriched PBMC have supported direct use of 
iNKT with evidence for immunological and objective clinical 
responses (59–62).
The first of these adoptive iNKT  cell therapies targeted 
six patients with non-small cell lung cancer (59). To grow out 
iNKT  cells, bulk PBMCs were stimulated two to three times 
via addition of α-GalCer to the cultured cells. These iNKT cell-
enriched products were then infused back into the patient, 
and the iNKT  cell numbers, persistence, and phenotype were 
measured. In most patients, there was a transient but not long-
term increase in iNKT  cell number within the blood, and this 
coincided with the ability to detect IFNγ production ex vivo via 
α-GalCer stimulation of PBMCs. Only minor adverse effects were 
seen in this first trial, demonstrating that adoptive cell therapy of 
iNKT cells is likely to be safe. In this study, no partial or complete 
responses were seen (59).
The next adoptive iNKT cell-based therapy studies combined 
autologous iNKT  cell-enriched product with in  vivo boosting. 
In a Phase I and subsequent Phase II study, the trial group first 
treated head and neck squamous cell carcinoma (HNSCC) 
patients with two doses of α-GalCer-loaded DCs followed by an 
iNKT cell infusion (60). In the Phase I trial, three patients showed 
partial responses, four had stable disease, and one had progressive 
disease (60). Of the eight patients, only one had grade 3 adverse 
events and that patient also had a partial response: a fistula formed 
within the tumor apparently due to rapid tumor killing (60). In 
the follow-up Phase II trial for 10 patients with HNSCC, patients 
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were first given nasal submucosal administration of α-GalCer 
loaded DCs followed by iNKT  cell infusion directly into the 
tumor-feeding arteries, so that iNKT cells were more likely to end 
up in the tumor site (61). Adverse events were minimal and lim-
ited to grade 2 or below, five patients had a partial response, and 
five patients had stable disease (61). iNKT cell numbers within 
the tumor and in the peripheral blood were measured, and while 
iNKT cell numbers in the blood did increase in 9 of 10 patients 
post-treatment, this did not correlate with outcome. Instead, a 
high number of tumor-infiltrating iNKT cells correlated with an 
objective response of patients (61).
With clinical colleagues at Harvard Cancer Center, we per-
formed a Phase I clinical trial of autologous purified [with the 
iNKTCR mAb 6B11 (62)] and expanded iNKT cells in nine mela-
noma cancer patients (62). In our study, iNKT cells were isolated 
from PBMCs with a protocol based on a monoclonal antibody 
that specifically recognizes the invariant TCR of iNKT cells and 
then expanded in  vitro with plate bound anti-CD3 antibody 
(62–64). Compared to previous studies using α-GalCer stimulated 
PBMCs as a source of iNKT cells (59–61), this study transferred 
in generally higher purity and/or larger numbers of iNKT cells 
(3 doses at up to 250 million iNKT cells per dose). Since iNKT cells 
are activated via interaction with CD1d on APC, after the first 
three patients had no significant toxicities, subsequent patients 
were pre-treated with GM-CSF to enhance DC functions before 
iNKT infusion cycles 2 and 3. Like in the other studies, we noted 
a transient increase in circulating iNKT cell numbers following 
adoptive cell transfer and increased activation of other T  cells 
and myeloid cells in some patients, and toxicities were minor and 
readily treatable (Grade 1 & 2 only) (62). In terms of responses 
at the end of the study, three patients had no evidence of disease 
or stable disease, three eventually progressed and responded to 
subsequent treatment, and three died of disease (one removed 
from study after infusions, two at 2 or more years post-treatment). 
Overall, our trial confirms that iNKT cell adoptive therapy is safe 
and well-tolerated, but modified treatment regimens are likely 
required to demonstrate efficacy. These could include further 
conditioning with stimulations like α-GalCer (on APC or free) 
and/or IL-12 in vivo.
FUTURe CLiNiCAL TRiALS: CAR-iNKT 
AND rTCR-iNKT
Current clinical trials with either α-GalCer-loaded Mo-DCs 
or adoptive transfer of iNKT  cells have produced partial and 
complete responses, but few if any cures in late stage patients. In 
contrast, T cells expressing chimeric antigen receptors (CAR-T) 
targeting surface proteins like CD19 have shown complete 
response rates of up to 90% in specific diseases such as B-ALL, 
leading to the first approvals for these treatments (65). Additional 
T cell therapies are utilizing recombinant TCR (rTCR-T) express-
ing T cells to be able to target peptides from tumor-associated 
intracellular proteins within the context of HLA molecules and 
are reporting similar complete response rates in myeloma (66) 
and solid malignancies.
One of the major drawbacks of CAR-T/rTCR-T cell therapy 
is a very high rate of serious adverse effects, including cytokine 
release syndrome (CRS) and lethal neurotoxicity (65, 67). Other 
risks include antigen selection issues (e.g., off-tumor on-target) 
and GvHD caused by TCR mispairing in rTCR-expressing cells 
and via allogeneic cell therapy (67). Interestingly, while GvHD 
is a common concern for both CAR-T and rTCR-T, iNKT cells 
have been shown in pre-clinical models to suppress, not cause 
GvHD and are associated with reduced GvHD in the clinic (19–
21, 68, 69), making for a potentially safer therapeutic approach. 
In light of both the promises and drawbacks of CAR-T and 
rTCR-T cells, there is growing interest in utilizing iNKT cells 
as an ideal platform for CAR or rTCR therapies (CAR-iNKT or 
CAR-rTCR).
One of the main benefits of considering iNKT  cells as an 
ideal vector for CAR/rTCR therapies is that iNKT cells have an 
endogenous TCR that is confirmed to have intrinsic anti-tumor 
capabilities (Figure 3). While the “random” endogenous TCRs on 
a bulk polyclonal T cell preparations are unlikely to contribute to 
anti-tumor effects, it is likely that iNKT cells could utilize both 
their endogenous TCR and their CAR/rTCR to target the tumor 
with two different targeting moieties. As mentioned previously, 
this could be by direct CD1d targeting either on the surface of the 
tumor cell or a bystander tumor-promoting myeloid cell, or via 
removing immunosuppression by killing CD1d + TAMs. Since 
strong TCR signaling cascades (as evidenced by potent iNKT cell 
antigens like α-GalCer) help cause Th1-based iNKT cell responses, 
having a second TCR signaling pathway engaged within the 
iNKT cell may help ensure that the iNKT cells remain Th1-biased 
in  vivo. Another advantage for CAR-iNKT or rTCR-iNKT  cell 
therapies is that iNKT cells naturally migrate into non-lymphoid 
tissues (70), suggesting that they would be ideal cells to target 
non-lymphoid tumors. Indeed, PLZF expression seems to drive 
innate T  cells tissue homing in general (4, 71). iNKT  cells are 
known to respond to tissue chemokines CCL2 (72) and CCL20 
(45). While suggestive of intrinsic benefits of iNKT cells, these 
points remain to be formally tested in the context of CARs in 
the clinic.
The Metelitsa group has pioneered CAR-iNKT cells for tumor 
therapies. In pre-clinical models, they have tested human iNKT cells 
purified with the iNKTCR mAb 6B11 for their ability to express 
GD2 CARs (against neuroblastomas) and CD19 CARs (against 
B cell lymphomas) (73, 74). Importantly, they demonstrated that 
iNKT cells could stably express either CAR construct, and that 
the CAR-iNKT cells kill relevant antigen-expressing tumor cell 
lines in vitro. With GD2 CAR-iNKT, this included killing of both 
GD2 +  CD1d− cells and GD2− CD1d +  cells, demonstrating 
that the endogenous iNKT TCR was still functional within GD2 
CAR-iNKT cells (73). Importantly, CAR-iNKT cell homing and 
killing in vivo of either the solid tumor xenograft model GD2-
expressing neuroblastoma or liquid xenograft B cell lymphoma 
was greatly increased over non-transduced iNKT cells, leading to 
substantially increased survival of CAR-iNKT treated mice (73).
As tumor homing and GvHD are concerns for both CAR-T 
and rTCR-T, they further measured if CAR-iNKT cells had better 
trafficking to the tumor and what effect placing the CAR into 
bulk T cells or iNKT cells had on GvHD. CAR-iNKT cells homed 
to the tumor at an even higher frequency than CAR-T  cells, 
providing evidence that iNKT cells do indeed have better tumor 
FigURe 3 | Invariant NKT (iNKT) cells are a viable cell vector for emerging CAR and rTCR therapies. Unlike bulk T cell preparations that are currently used for 
chimeric antigen receptor (CAR) or recombinant TCR (rTCR) T cell therapies, the endogenous iNKT-TCR has anti-tumor function (left side). In contrast, the bulk T cell 
endogenous TCRs do not contribute to the anti-tumor function of the cell (middle picture). Instead, the bulk T cell endogenous TCR is a liability, endowing the cells 
with the potential for graft versus host disease (GvHD) or other off-target effects. While GvHD is a common concern for both CAR-T and rTCR-T allogeneic therapy 
and at least a possibility due to mispairing for autologous rTCR-iNKT, iNKT cells are shown in pre-clinical models to suppress, not cause GvHD during allogeneic 
transfer, making for a safer therapeutic approach. Additionally, iNKT cells expressing a CAR or rTCR (right picture) would be endowed with two different anti-tumor 
receptors. This would allow iNKT cells to target the tumor directly with the CAR or rTCR while its endogenous iNKT-TCR would be able to target the tumor 
microenvironment and/or the tumor itself, depending on if the tumor expressed CD1d. Either way, CAR-iNKT and rTCR-iNKT therapies would have an endogenous 
TCR that contributes to tumor clearance instead of be a hindrance.
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homing than bulk T  cells (73). To model GvHD within the 
context of a xenogeneic cell transfer, CAR-iNKT or CAR-T cells 
were transferred into humanized mice and monitored for GvHD. 
As would be expected when transferring in xenogeneic T cells, 
CAR-T cells caused severe GvHD in the livers and lungs of the 
mice. In contrast, CAR-iNKT cells did not cause GvHD of these 
organs during xenogeneic transfer (73), consistent with the 
GvHD suppressing activities of iNKT described above. Finally, 
additional work suggested that in GD2 CARs, expression of 
both the CD28 and 4-1BB costimulatory domains led to longer 
CAR-iNKT persistence and increased survival of mice compared 
to single CD28 or 4-1BB costimulatory domains (73). As well as 
the Metelitsa group, Karadimitris et al. reported in a review oth-
erwise of potential myeloma treatments that CD19-CAR iNKT 
had promising preclinical anti-tumor activity in their hands also 
(75). Both groups are planning clinical trials in the near future.
Many groups are looking at transducing subsets of T  cells 
for CAR/rTCR therapies, and some studies have suggested that 
CD62L+ (central memory) T cells are superior to other T cell 
subsets (76). In the Metelitsa group CD19 CAR-iNKT study, 
Tian et  al. separated CD62L+ and CD62L− CAR-iNKT  cells 
and measured their persistence and anti-tumor ability (74). 
CD62L+ CAR-iNKT  cells had superior proliferation, in  vivo 
persistence, and antitumor activity as compared to the CD62L− 
CAR-iNKT  cells (74), suggesting that even with iNKT  cells, it 
may be worthwhile to target a defined subset for CAR-iNKT 
or rTCR-iNKT therapies. Interestingly, the majority of iNKT 
express CD62L until they are repeatedly stimulated in vitro (74). 
While these CAR-iNKT preclinical studies are extremely valu-
able, critical issues should be generalized within future studies. 
First, multiple in vivo comparisons of tumor killing and survival 
of CAR-iNKT to bulk T cell CAR-T cells should be performed. 
Second, as in vivo administration of α-GalCer is well tolerated 
in humans, it should be determined if α-GalCer administration 
could help either expand CAR-iNKT in vivo and/or cause an addi-
tive/synergistic increase in anti-tumor activity. Planned clinical 
studies will begin to address these issues in the near future.
Jiang et al. have provided the first evidence of iNKT cells being 
able to express a second recombinant TCR (77). In this study, 
a HLA class I-restricted TCR (TCR-Vα9 TCR-Vβ5) against the 
Mycobacterium tuberculosis (Mtb) 38-kDa protein was cloned and 
expressed in iNKT cells. Using autologous 38-kDa protein pulsed 
Mo-DCs as APC, they confirmed that only rTCR-expressing 
iNKT cells recognized and killed these cells. The relative killing 
efficiency of α-GalCer-pulsed Mo-DCs was similar to the kill-
ing of 38-kDa pulsed Mo-DCs, suggesting that the endogenous 
iNKT TCR was still fully functional (77). However, it was not 
determined if the recombinant TCR and the endogenous TCR 
could both signal at the same time to cause additive or synergistic 
effects. Nor was it determined if expression of the recombinant 
TCR came at the expense of some endogenous iNKT-TCR, as 
could happen due to competition for CD3 complexes. Finally, as 
it has been reported that the anti-Mtb activity of iNKT cells is 
due to production of GM-CSF and not production of IFNγ or 
infected cell lysis (78), it is unclear what additional role(s) rTCR-
iNKT cells would play during Mtb infection. Future studies are 
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needed to determine if expressing this rTCR in iNKT cells skews 
their function in vivo during Mtb infection, either by helping traf-
ficking of iNKT cells to the site of infection or otherwise. Clearly, 
iNKT expressing anti-tumor rTCR could also gain augmented 
activity, as is currently being addressed by some groups.
CONCLUSiON
iNKT cells provide a novel alternative to standard T cells in cancer 
immunotherapy, as described above. Their tissue (and therefore 
also tumor) tropism, inherent direct and indirect anti-tumor 
activities and our ability to manipulate them in vitro and in vivo 
(e.g., with α-GalCer, analogs thereof, or the iNKTCR mAb 6B11) 
combined with reversible defects in cancer patients suggest that 
they can be exploited to treat a range of solid and hematological 
malignancies.
An important potential caveat in exploiting iNKT  cells 
has been the observation that repeated stimulation of mouse 
iNKT cells (though less so with human iNKT) with α-GalCer can 
lead to an anergic-like state (3–6, 8, 79–81). Interestingly, this 
state can be reversed by PD-1/PD-L1 blockade (79), commonly 
now used in the clinic to overcome conventional anti-tumor 
responses. Furthermore, it may reflect a polarization to IL-10 
producing “NKT10” that have been found in mice and man 
(81). Another promising approach in general, which may also 
overcome NKT  cell anergy/polarization, is differential use of 
co-stimulation alongside direct invariant TCR stimulation (82).
There may well be more total “non-invariant” diverse CD1d-
restricted NKT cells in the body than iNKT and their ability to 
make Th2 cytokines appears to impair tumor immunity (30), 
whereas such NKT making IFNγ stratifies with cancer patient 
survival (83), as does iNKT (24, 25, 54). However, non-invariant 
CD1d-restricted NKT cell manipulation is much more challeng-
ing and their understanding lags far behind iNKT cells. Finally, 
unlike other innate lymphocytes like NK and γδ T cells, iNKT 
are also relatively rare, so substantially increasing their numbers 
should be safe and is both very feasible (as described above) and 
has more potential to change the milieu (the other populations 
at ~5% of total lymphocytes probably cannot be increased more 
than ~10-fold without concomitant loss of conventional T cells). 
The next few years should provide an opportunity for iNKT cells 
to “put up or shut up”!
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